Christine L. Brakel, et al.

Serial No.: 446,235

Filing Date: December 4, 1989

Page 2 - (Reconsideration Of Restriction Requirement Under

37 C.F.R. §1.143) - May 31, 1991

Page 19, line 17, after "oligodeoxynucleotide" and after "14-P-3" insert a comma -- , --, both occurrences.

Page 19, line 18, after oligodeoxynucleotides" and "14-C-3" insert a comma -- , --, both occurrences.

Page 21, line 6, after "cleavage of" and before "oligodeoxynucleotides" insert -- methylphosphonate-substituted --.

Page 21, line 6, after "oligodeoxynucleotide" insert a comma -- , --.

In the Claims:

Add new claim 51 as follows:

Of Sold

--51. (New) A modified nucleotide compound which comprises at least one component selected from the group consisting of MN_3M , $B(N)_xM$ and $M(N)_xB$ wherein:

N comprises a phosphodiester-linked modified 2'-deoxynucleoside moiety;

M is a moiety that confers endonuclease resistance on said component and which comprises at least one nucleic acid base modified with a 3'-methylphosphonate;

B is a moiety that confers exonuclease resistance to the terminus to which it is attached and comprises a 2',3'-dideoxyribose nucleotide; and

x is an integer of about 2.--
